Frank Griesinger, MD, PhD from the Pius-Hospital Oldenburg, Oldenburg, Germany discusses the role of p53 mutation in EGFR mutation positive (M+) non-small cell lung cancer (NSCLC). Prof. Griesinger explains that they looked EGFR-mutated patients to see if an additional genetic alteration, i.e. a p53 mutation, has an impact of survival; it does seem to have an impact on progression-free survival (PFS) and overall survival (OS), which are inferior in patients with p53 mutation. Further, there are pathogenic and non-pathogenic p53 mutations and this also has an impact on survival. He explains that patients should be tested for the mutation and to have drugs that target p53. Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.